Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Bromantane and Pinealon — mechanism, dosing, side effects, legal status, and pricing.
Bromantane (Ladasten) is a synthetic adamantane-derivative small molecule — not a peptide — developed in Russia as an "actoprotector"/adaptogen with combined mild psychostimulant and anxiolytic activity. It is an approved prescription drug in Russia (Ladasten) for asthenic disorders, but it has no FDA or EMA approval and no blinded, placebo-controlled human trials. It is prohibited in sport (WADA S6 stimulant) and circulates on the gray market as a research chemical.
Bromantane
Pinealon
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Bromantane
No pricing data yet.
Check Bromantane prices →Pinealon
COA corpus from Disclosed Labs — independently tested batches only.
Bromantane
4
COAs
99.9%
Avg purity
3
Labs
Pinealon
30
COAs
98.7%
Avg purity
9
Labs
Human evidence is limited to Russian clinical use of Ladasten. The largest published dataset is an open-label, non-comparative multicenter trial (28 centers, N=728) in asthenic disorder at 50–100 mg/day for 28 days (Voznesenskaia et al., 2010), reporting symptomatic improvement (CGI-S response 76.0%, CGI-I 90.8%) with adverse effects in ~3% of patients. No blinded, placebo-controlled randomized trial exists and there is no ClinicalTrials.gov registration. All mechanistic and toxicology data are preclinical (rat, mouse, in-vitro). Approved only in Russia; not FDA/EMA-approved; not a peptide.
Key references
Khavinson et al. (Rejuvenation Research, 2011, PMID 21978084) reported that Pinealon suppressed reactive oxygen species accumulation, reduced cell death, and modulated cell-cycle progression across multiple cell types under oxidative stress, with the authors suggesting direct genome-level interaction. Arutjunyan et al. (International Journal of Clinical and Experimental Medicine, 2012, PMID 22567179) reported that Pinealon administered to pregnant rats on a methionine (hyperhomocysteinemia) diet improved spatial learning and reduced ROS accumulation in cerebellar neurons of offspring. The evidence base is dominated by Khavinson's St. Petersburg Institute of Bioregulation and Gerontology and has not been independently replicated in Western clinical trials. No Phase II or III trials exist; Pinealon is not FDA-approved.
Bromantane and Pinealon are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs